Jarrad Mattieu Aguirre
Chief Medical Officer · Lyell Immunopharma, Inc.
- 2026
- Oct 13, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Jarrad Mattieu Aguirre files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ARCH Venture Fund XIII, L.P. - $12.50M in LYEL purchases and sales in the last 12 months
- ARCH Venture Partners IX, LLC - $12.50M in LYEL purchases and sales in the last 12 months
- Lynn Seely - $353K in LYEL purchases and sales in the last 12 months
- Gary K. Lee - $72K in LYEL purchases and sales in the last 12 months
- Stephen J. Hill - $51K in LYEL purchases and sales in the last 12 months
- David Shook - $31K in LYEL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Jarrad Mattieu Aguirre?
Jarrad Mattieu Aguirre is a corporate insider, tracked as Chief Medical Officer of Lyell Immunopharma, Inc. (LYEL). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jarrad Mattieu Aguirre submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Jarrad Mattieu Aguirre been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($4K) across all tracked filings.
